Amivantamab Side Effects

Amivantamab (Amivantamab) is a targeted therapy used to treat specific subtypes of non-small cell lung cancer (NSCLC), including EGFR Patients with span>gene mutations and METgene exon 14 deletion (METex14). While the drug is expected to provide therapeutic benefits to patients, like other drugs, evantumumab may cause some side effects. Here are some of the main side effects associated with evantumumab to help patients and doctors better understand and manage potential risks.

1. Common side effects:

1.Skin Reactions: Evantumumab treatment may cause skin reactions such as rash, itching, dry skin, and pain. These symptoms are usually mild to moderate, but may sometimes require special skin care and treatment.

2.Nausea and Vomiting: Patients may experience mild to moderate nausea and vomiting while receiving evantumumab. Your doctor can recommend nausea-controlling medications to reduce these symptoms.

3.Fatigue: Fatigue is another common side effect that may affect patients' daily activities. Patients need adequate rest and appropriate exercise to reduce fatigue.

4.Headache: Some patients may experience headache, which is usually mild. Your doctor may consider offering medications to relieve your headache.

5.Loss of appetite: Evantumumab treatment may affect appetite, resulting in reduced food intake. It is important to maintain a healthy diet and eat regularly.

6.Diarrhea: Diarrhea is also a possible side effect. Patients need to maintain adequate fluid intake to prevent dehydration.

7.Muscle pain: Some patients may experience mild muscle pain, which may require rest and mild physical activity.

2. Serious adverse reactions:

Although common side effects of evantumumab are generally mild, in some cases, serious adverse reactions may occur and require prompt intervention and management. These serious adverse reactions may include:

1.Allergic reaction: Some patients may be allergic to evantumumab and experience allergic reactions, such as skin rash, shortness of breath, throat swelling, etc. Severe allergic reactions require immediate medical attention.

2.Dyspnea: In rare cases, treatment with evantumumab may cause dyspnea. Patients should inform their doctor promptly so the severity of symptoms can be assessed.

3.Bleeding: Evantumumab may increase the risk of bleeding. Patients should closely monitor signs of bleeding, such as nosebleeds, hemorrhagic colitis, etc., so that they can seek medical attention promptly.

3. Warnings and precautions:

Patients and physicians should pay attention to the following while using evantumumab:

1.Monitoring and follow-up: Patients need to receive regular follow-up and monitoring from doctors to evaluate the treatment effect and monitor adverse reactions.

2.Pregnancy and Contraception: Evantumumab may cause risks to the fetus, so patients should avoid becoming pregnant during treatment and use appropriate contraceptive measures.

3.Drug Interactions: Patients should inform their doctors of other medications they are taking to avoid potential drug interactions.

4. Medication for special groups:

For elderly patients, patients with impaired liver and kidney function, and other special groups, the dosage and usage of evantumumab may need to be adjusted according to the specific situation, and doctors will develop an individualized treatment plan based on the patient's needs.

In general, evantuzumab is a drug that is expected to provide new treatment options for patients with EGFR gene mutations and METex14 deletions NSCLC. Although it promises significant therapeutic benefits, both patients and physicians should be aware of side effects and potential adverse reactions so that timely steps can be taken to manage and mitigate these risks to achieve optimal treatment outcomes and survival.

Evantuzumab is not yet available in China, so patients cannot purchase it domestically and need to purchase it through foreign channels. There are only European versions of original drugs available abroad, and the price is relatively high, around 20,000 yuan.